GlassScriptPhysician profile
John J Destafeno
NPI 1912097171
$23,800.72
in general payments reported to CMS, 2019-2025
27 companies · $2,138 in 2025
The $2,138 reported for 2025 was more than what 89% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,967 · 2020: $3,106 · 2021: $3,819 · 2022: $3,602 · 2023: $894 · 2024: $3,275 · 2025: $2,138.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,634 · Consulting Fee: $1,673.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,634.29 |
| Consulting Fee | $1,672.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $11,547.41 | 2019-2025 | Cequa |
| Alcon Vision LLC | $5,464.30 | 2019-2025 | Clareon, Clareon Panoptix Pro, Unity |
| Johnson & Johnson Surgical Vision, INC. | $2,465.14 | 2021-2024 | Tecnis Iol, Tecnis Simplicity |
| Carl Zeiss Meditec, INC. | $1,268.90 | 2022-2024 | Veracity Surgical, Visumax, Cirrus Hd-Oct |
| New World Medical,INC. | $700.00 | 2022 | |
| Bausch & Lomb Americas INC. | $319.92 | 2023-2025 | Xiidra, Miebo |
| Tarsus Pharmaceuticals, INC. | $285.52 | 2024-2025 | Xdemvy |
| Allergan, INC. | $265.62 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $237.89 | 2019-2023 | |
| Carl Zeiss Meditec USA, INC. | $210.46 | 2023 | Iolmaster 700, Quatera 700 |
| Oyster Point Pharma, INC. | $177.37 | 2022-2025 | Tyrvaya, Ryzumvi |
| Regeneron Healthcare Solutions, INC. | $124.03 | 2022-2025 | Eylea Hd, Eylea |
| Dompe US, INC. | $115.10 | 2019-2025 | Oxervate |
| Kala Pharmaceuticals, INC. | $111.80 | 2019-2021 | |
| Harrow Eye, LLC | $93.96 | 2024-2025 | Vevye |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $70.12 | 2019-2021 | |
| Biotissue Holdings INC. | $70.10 | 2020-2024 | |
| Rxsight INC | $61.60 | 2024 | Rxsight Injector Cartridge, Rxsight Contact Lens, Light Adjustable Lens (Lal) |
| Abbvie INC. | $40.42 | 2022-2024 | |
| Ani Pharmaceuticals, INC. | $39.98 | 2025 | Yutiq, Iluvien |
| Genentech USA, INC. | $38.74 | 2024 | Lucentis, Vabysmo |
| Akorn, INC. | $21.83 | 2019 | |
| Rayner Intraocular Lenses Limited | $21.19 | 2023 | Omidria, Rayone Aspheric, Rayone Emv |
| Omeros Corporation | $19.31 | 2019 | |
| Apellis Pharmaceuticals, INC. | $15.77 | 2023 | Syfovre |
| Shire North American Group INC | $14.24 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$299,808.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Destafeno listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.